Table 1 Characteristics of study population in the derivation and validation cohorts
From: Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study
Variable | Derivation (n = 200) | Validation (n = 200) | p |
|---|---|---|---|
Age | 60 (49.5–69) | 67 (59–78) | < 0.001 |
Male gender | 110 (55.0%) | 105 (52.5%) | 0.62 |
Race | |||
 Caucasian | 110 (55.0%) | 106 (53%) | < 0.001 |
 African American | 82 (41.0%) | 24 (12.0%) | |
 Asian | 4 (2.0%) | 50 (25.0%) | |
 Other | 4 (2.0%) | 20 (10.0%) | |
Diabetes mellitus | 59 (29.5%) | 57 (28.5%) | 0.83 |
Cirrhosis | 20 (10.0%) | 17 (8.5%) | 0.61 |
Immunocompromised | 95 (47.5%) | 27 (13.5%) | < 0.001 |
Pneumonia | 78 (39.0%) | 104 (52.5%) | 0.007 |
APACHE II | 25 (19.5–32.5) | 25 (19–33) | 0.99 |
Septic shock at presentation | 77 (38.5%) | 98 (49.0%) | 0.034 |
Invasive ventilation at presentation | 82 (41.0%) | 82 (41.0%) | 1.0 |
ARDS | 57 (28.5%) | 50 (25.3%) | 0.47 |
30-day mortality | 82 (41.0%) | 54 (27.0%) | 0.003 |
sTNFR1 (pg/ml) | 8444 (4332–13,450) | 6366 (3232–11,024) | 0.004 |
IL8 (pg/ml) | 115.7 (51.2–325.6) | 54.7 (23.5–241.0) | < 0.001 |
Ang2 (pg/ml) | 13,933 (8747–26,865) | 13,894 (7146–24,447) | 0.24 |